Therna and Charles River Collaborate to Develop Personalized RNA Therapies for Rare Disorders Therna Biosciences partners with Charles River to create tailored RNA treatments for patients with ultra-rare disorders, using AI technology for fast development.

Therna and Charles River Collaborate to Develop Personalized RNA Therapies for Rare Disorders #United_States #San_Francisco #RNA_Therapies #Charles_River #Therna_Biosciences

The Future of Cardiovascular Biologics: Projected Growth to USD 4.23 Billion by 2033 The cardiovascular biologics market, driven by RNA therapies, is anticipated to reach USD 4.23 billion by 2033, highlighting a 7.5% CAGR fueled by innovative treatments addressing cardiovascular diseases.

The Future of Cardiovascular Biologics: Projected Growth to USD 4.23 Billion by 2033 #United_States #Austin #RNA_Therapies #Monoclonal_Antibodies #Cardiovascular_Biologics

RNA Horizons 2025 in Palermo: Innovations Reshaping RNA Therapeutics Landscape The RNA Horizons Therapeutics Symposium 2025 brought together global experts in Palermo to discuss breakthroughs in RNA therapies for various diseases.

RNA Horizons 2025 in Palermo: Innovations Reshaping RNA Therapeutics Landscape #Italy #RNA_Therapies #Palermo #RNA_Horizons

iOncologi's Patented RNA Innovations Promise Enhanced Cancer Immunotherapy Outcomes iOncologi has secured a key U.S. patent for RNA-based cancer therapies, connecting COVID-19 mRNA vaccines to improved immunotherapy responses.

iOncologi's Patented RNA Innovations Promise Enhanced Cancer Immunotherapy Outcomes #United_States #Gainesville #Cancer_Immunotherapy #RNA_Therapies #iOncologi

Duchenne Muscular Dystrophy Therapeutics Market Projected to Reach $6.6 Billion by 2033 Amidst Revolutionary Therapies The Duchenne Muscular Dystrophy therapeutics market is set to experience dramatic growth, moving from $2.19 billion in 2024 to $6.64 billion by 2033, thanks to gene and RNA therapies redefining treatment protocols.

Duchenne Muscular Dystrophy Therapeutics Market Projected to Reach $6.6 Billion by 2033 Amidst Revolutionary Therapies #None #gene_therapy #RNA_Therapies #Duchenne_Muscular_Dystrophy

Tsingke Biotech Hosts Pivotal Roundtable for Small Nucleic Acid Therapies in Beijing On July 26, 2025, Tsingke Biotech gathered experts in Beijing to discuss advances in small nucleic acid therapeutics and their commercialization.

Tsingke Biotech Hosts Pivotal Roundtable for Small Nucleic Acid Therapies in Beijing #China #Beijing #RNA_Therapies #Tsingke_Biotech #Nucleic_Acid

Myeloid Therapeutics to Showcase Innovative Cancer RNA Therapies at JP Morgan Healthcare Conference Myeloid Therapeutics, a clinical-stage immunology company, will present its innovative RNA therapies at the JP Morgan Healthcare Conference, promising advancements in cancer treatment.

Myeloid Therapeutics to Showcase Innovative Cancer RNA Therapies at JP Morgan Healthcare Conference #United_States #Cambridge #JP_Morgan #Myeloid_Therapeutics #RNA_Therapies